Likarda announces core shell spherification for large molecule biologics and welcomes new ceo, dr. stella vnook

Cambridge, mass.--(business wire)--likarda, llc, a pioneering cell therapy company, is at the forefront of creating advanced delivery systems that enhance the efficacy of cell therapies. central to their innovative approach is the core-shell spherification® (css®) platform technology, designed to significantly elevate treatment outcomes. in a significant move for the biologics industry, likarda is proud to announce two major developments: the expansion of its core shell spherification (css) tec.
SHEL Ratings Summary
SHEL Quant Ranking